It’s our mission to deliver innovative therapies to improve the lives of patients impacted by cancer and autoimmune diseases.

MorphoSys' mission

MorphoSys mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Our focus is on cancer. Innovative technologies and smart development strategies are central to our approach.

11/05/2021
MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND...
05/05/2021
MorphoSys AG Reports First Quarter 2021 Results
28/04/2021
Invitation to MorphoSys' First Quarter Results Conference Call on May...
19/04/2021
MorphoSys and Incyte Announce First Patient Dosed in Phase 3 inMIND Study...
15/03/2021
MorphoSys AG Presents Results for Full Year 2020
09/03/2021
Invitation to MorphoSys' Full Year Results 2020 Conference Call on...
02/03/2021
MorphoSys's Licensing Partner GSK Shared Preliminary Results From...
01/03/2021
Ad hoc: MorphoSys AG preliminary results for the fiscal year 2020...
25/01/2021
MorphoSys AG: MorphoSys and I-Mab Announce First Patient Dosed in U.S....
12/01/2021
MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug...